glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential therapeutic benefits for MASLD patients, including improvements in liver function, inflammation, and fibrosis. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.